Ascribe Bio’s new collaboration with Corteva points to a larger shift in AgTech: crop biologicals are moving closer to the seed, where the agronomy is tougher, the economics are harsher, and the commercial upside may be much bigger.
When Ascribe Bio and Corteva said this week that they would work together on seed-treatment uses for Phytalix, the announcement could have been mistaken for a narrow product-development update. In reality, it signals something more consequential. For years, biological crop protection has tried to prove it belongs inside mainstream farm programs rather than at the edges of them.
